Profile data is unavailable for this security.
About the company
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2021
- Employees24.00k
- LocationHaleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
- Phone+44 193 282 2000
- Websitehttps://www.haleon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Pharma plc | 2.38bn | 770.95m | 26.07bn | 100.00 | 25.38 | 4.03 | 29.14 | 10.96 | 1.78 | 1.78 | 4.21 | 11.22 | 0.1257 | -- | 84.52 | 23,781,930.00 | 7.00 | 6.72 | 9.03 | 9.10 | -- | -- | 55.68 | 50.56 | -- | 7.06 | 0.4795 | 50.52 | 5.06 | 2.30 | -10.25 | 9.26 | -4.90 | 24.01 |
| Biogen Inc | 9.89bn | 1.29bn | 28.84bn | 7.50k | 22.32 | 1.58 | 13.91 | 2.92 | 8.81 | 8.81 | 67.37 | 124.45 | 0.3441 | 1.04 | 5.30 | 1,318,747.00 | 4.50 | 6.70 | 5.32 | 7.93 | 75.69 | 78.49 | 13.07 | 17.28 | 2.03 | 5.74 | 0.2562 | 0.00 | 2.22 | -5.96 | -20.79 | -20.22 | -19.60 | -- |
| Alnylam Pharmaceuticals, Inc. | 3.71bn | 313.75m | 41.70bn | 2.50k | 140.03 | 52.74 | 112.88 | 11.23 | 2.25 | 2.25 | 27.82 | 5.96 | 0.8068 | 8.46 | 7.20 | 1,485,575.00 | 6.82 | -12.28 | 9.57 | -16.14 | 81.64 | 83.20 | 8.45 | -24.70 | 2.71 | 3.50 | 0.7737 | -- | 65.19 | 49.77 | 212.79 | -- | -3.56 | -- |
| Haleon PLC - ADR | -100.00bn | -100.00bn | 49.34bn | 24.00k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.67 | -- | 4.23 | -- | 62.28 | -- | 11.97 | 0.6327 | -- | 0.3464 | 218.58 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| Zoetis Inc | 9.47bn | 2.67bn | 53.46bn | 14.50k | 21.03 | 16.16 | 16.90 | 5.65 | 6.02 | 6.02 | 21.33 | 7.84 | 0.6374 | 1.12 | 6.52 | 652,896.60 | 18.00 | 16.21 | 22.22 | 19.61 | 71.89 | 70.69 | 28.23 | 27.03 | 1.94 | 20.97 | 0.7308 | 29.07 | 2.28 | 7.24 | 7.52 | 10.29 | 6.51 | 20.11 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Dec 2025 | 151.76m | 3.41% |
| Strategic Advisers LLCas of 30 Sep 2025 | 53.07m | 1.19% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 36.04m | 0.81% |
| ClearBridge Investments LLCas of 31 Dec 2025 | 31.42m | 0.71% |
| Harding Loevner LPas of 30 Sep 2025 | 17.91m | 0.40% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 16.18m | 0.36% |
| FIAM LLCas of 30 Sep 2025 | 14.89m | 0.33% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 12.80m | 0.29% |
| Sculptor Capital LPas of 31 Dec 2025 | 10.45m | 0.24% |
| Natixis Advisors LLCas of 31 Dec 2025 | 10.00m | 0.23% |
